144 related articles for article (PubMed ID: 37813196)
1. Trivalent nanobody-based ligands mediate powerful activation of GPVI, CLEC-2, and PEAR1 in human platelets whereas FcγRIIA requires a tetravalent ligand.
Martin EM; Clark JC; Montague SJ; Morán LA; Di Y; Bull LJ; Whittle L; Raka F; Buka RJ; Zafar I; Kardeby C; Slater A; Watson SP
J Thromb Haemost; 2024 Jan; 22(1):271-285. PubMed ID: 37813196
[TBL] [Abstract][Full Text] [Related]
2. Divalent nanobodies to platelet CLEC-2 can serve as agonists or antagonists.
Clark JC; Martin EM; Morán LA; Di Y; Wang X; Zuidscherwoude M; Brown HC; Kavanagh DM; Hummert J; Eble JA; Nieswandt B; Stegner D; Pollitt AY; Herten DP; Tomlinson MG; García A; Watson SP
Commun Biol; 2023 Apr; 6(1):376. PubMed ID: 37029319
[TBL] [Abstract][Full Text] [Related]
3. Significant Hypo-Responsiveness to GPVI and CLEC-2 Agonists in Pre-Term and Full-Term Neonatal Platelets and following Immune Thrombocytopenia.
Hardy AT; Palma-Barqueros V; Watson SK; Malcor JD; Eble JA; Gardiner EE; Blanco JE; Guijarro-Campillo R; Delgado JL; Lozano ML; Teruel-Montoya R; Vicente V; Watson SP; Rivera J; Ferrer-Marín F
Thromb Haemost; 2018 Jun; 118(6):1009-1020. PubMed ID: 29695020
[TBL] [Abstract][Full Text] [Related]
4. Distinct pathways regulate Syk protein activation downstream of immune tyrosine activation motif (ITAM) and hemITAM receptors in platelets.
Manne BK; Badolia R; Dangelmaier C; Eble JA; Ellmeier W; Kahn M; Kunapuli SP
J Biol Chem; 2015 May; 290(18):11557-68. PubMed ID: 25767114
[TBL] [Abstract][Full Text] [Related]
5. Dextran sulfate triggers platelet aggregation via direct activation of PEAR1.
Vandenbriele C; Sun Y; Criel M; Cludts K; Van Kerckhoven S; Izzi B; Vanassche T; Verhamme P; Hoylaerts MF
Platelets; 2016 Jun; 27(4):365-72. PubMed ID: 26619766
[TBL] [Abstract][Full Text] [Related]
6. The novel Syk inhibitor R406 reveals mechanistic differences in the initiation of GPVI and CLEC-2 signaling in platelets.
Spalton JC; Mori J; Pollitt AY; Hughes CE; Eble JA; Watson SP
J Thromb Haemost; 2009 Jul; 7(7):1192-9. PubMed ID: 19422460
[TBL] [Abstract][Full Text] [Related]
7. C-type lectin-like receptor-2 (CLEC-2) is a key regulator of kappa-carrageenan-induced tail thrombosis model in mice.
Yokomori R; Shirai T; Tsukiji N; Oishi S; Sasaki T; Takano K; Suzuki-Inoue K
Platelets; 2023 Dec; 34(1):2281941. PubMed ID: 38010137
[TBL] [Abstract][Full Text] [Related]
8. Galectin-9 activates platelet ITAM receptors glycoprotein VI and C-type lectin-like receptor-2.
Zhi Z; Jooss NJ; Sun Y; Colicchia M; Slater A; Moran LA; Cheung HYF; Di Y; Rayes J; Poulter NS; Watson SP; Iqbal AJ
J Thromb Haemost; 2022 Apr; 20(4):936-950. PubMed ID: 34936188
[TBL] [Abstract][Full Text] [Related]
9. CLEC-2 expression is maintained on activated platelets and on platelet microparticles.
Gitz E; Pollitt AY; Gitz-Francois JJ; Alshehri O; Mori J; Montague S; Nash GB; Douglas MR; Gardiner EE; Andrews RK; Buckley CD; Harrison P; Watson SP
Blood; 2014 Oct; 124(14):2262-70. PubMed ID: 25150298
[TBL] [Abstract][Full Text] [Related]
10. Experimental validation of computerised models of clustering of platelet glycoprotein receptors that signal via tandem SH2 domain proteins.
Maqsood Z; Clark JC; Martin EM; Cheung YFH; Morán LA; Watson SET; Pike JA; Di Y; Poulter NS; Slater A; Lange BMH; Nieswandt B; Eble JA; Tomlinson MG; Owen DM; Stegner D; Bridge LJ; Wierling C; Watson SP
PLoS Comput Biol; 2022 Nov; 18(11):e1010708. PubMed ID: 36441766
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Src but not Syk causes weak reversal of GPVI-mediated platelet aggregation measured by light transmission aggregometry.
Cheung HYF; Moran LA; Sickmann A; Heemskerk JWM; Garcia Á; Watson SP
Platelets; 2022 Nov; 33(8):1293-1300. PubMed ID: 35535424
[TBL] [Abstract][Full Text] [Related]
12. G6b-B inhibits constitutive and agonist-induced signaling by glycoprotein VI and CLEC-2.
Mori J; Pearce AC; Spalton JC; Grygielska B; Eble JA; Tomlinson MG; Senis YA; Watson SP
J Biol Chem; 2008 Dec; 283(51):35419-27. PubMed ID: 18955485
[TBL] [Abstract][Full Text] [Related]
13. Phosphorylation on Syk Y342 is important for both ITAM and hemITAM signaling in platelets.
Kostyak JC; Mauri B; Dangelmaier C; Vari HR; Patel A; Wright M; Reddy H; Tsygankov AY; Kunapuli SP
J Biol Chem; 2022 Aug; 298(8):102189. PubMed ID: 35753354
[TBL] [Abstract][Full Text] [Related]
14. The C-type lectin receptors CLEC-2 and Dectin-1, but not DC-SIGN, signal via a novel YXXL-dependent signaling cascade.
Fuller GL; Williams JA; Tomlinson MG; Eble JA; Hanna SL; Pöhlmann S; Suzuki-Inoue K; Ozaki Y; Watson SP; Pearce AC
J Biol Chem; 2007 Apr; 282(17):12397-409. PubMed ID: 17339324
[TBL] [Abstract][Full Text] [Related]
15. Activation of glycoprotein VI (GPVI) and C-type lectin-like receptor-2 (CLEC-2) underlies platelet activation by diesel exhaust particles and other charged/hydrophobic ligands.
Alshehri OM; Montague S; Watson S; Carter P; Sarker N; Manne BK; Miller JL; Herr AB; Pollitt AY; O'Callaghan CA; Kunapuli S; Arman M; Hughes CE; Watson SP
Biochem J; 2015 Jun; 468(3):459-73. PubMed ID: 25849538
[TBL] [Abstract][Full Text] [Related]
16. A novel Syk-dependent mechanism of platelet activation by the C-type lectin receptor CLEC-2.
Suzuki-Inoue K; Fuller GL; García A; Eble JA; Pöhlmann S; Inoue O; Gartner TK; Hughan SC; Pearce AC; Laing GD; Theakston RD; Schweighoffer E; Zitzmann N; Morita T; Tybulewicz VL; Ozaki Y; Watson SP
Blood; 2006 Jan; 107(2):542-9. PubMed ID: 16174766
[TBL] [Abstract][Full Text] [Related]
17. Akt and mitogen-activated protein kinase enhance C-type lectin-like receptor 2-mediated platelet activation by inhibition of glycogen synthase kinase 3α/β.
Moroi AJ; Watson SP
J Thromb Haemost; 2015 Jun; 13(6):1139-50. PubMed ID: 25858425
[TBL] [Abstract][Full Text] [Related]
18. Platelet adhesion to podoplanin under flow is mediated by the receptor CLEC-2 and stabilised by Src/Syk-dependent platelet signalling.
Navarro-Núñez L; Pollitt AY; Lowe K; Latif A; Nash GB; Watson SP
Thromb Haemost; 2015 May; 113(5):1109-20. PubMed ID: 25694214
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the GPVI inhibitors losartan and honokiol.
Onselaer MB; Nagy M; Pallini C; Pike JA; Perrella G; Quintanilla LG; Eble JA; Poulter NS; Heemskerk JWM; Watson SP
Platelets; 2020; 31(2):187-197. PubMed ID: 30849265
[TBL] [Abstract][Full Text] [Related]
20. Heparin and heparin proteoglycan-mimetics activate platelets via PEAR1 and PI3Kβ.
Kardeby C; Evans A; Campos J; Al-Wahaibi AM; Smith CW; Slater A; Martin EM; Severin S; Brill A; Pejler G; Sun Y; Watson SP
J Thromb Haemost; 2023 Jan; 21(1):101-116. PubMed ID: 36695374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
